CYP19A1 and breast cancer: For ER+ BC patients, endocrine therapies (ET) including selective estrogen receptor down-regulators (SERDs), aromatase inhibitors (AIs), and selective estrogen receptor modulators (SERMs) are critical, among which tamoxifen (TAM) is a mainstay of treatment in use [4].